Brief: Poxel End-September Revenue Up At 13.3 Million Euros

Poxel SA

20/10/2021 17:23

Oct 20 (Reuters) - Poxel SA  POXEL.PA :
    * PROVIDES CORPORATE UPDATE AND REPORTS CASH AND REVENUE FOR
Q3
AND NINE MONTHS 2021
    * TWYMEEG® (IMEGLIMIN HYDROCHLORIDE) LAUNCHED IN JAPAN ON
SEPTEMBER 16 FOR THE TREATMENT OF TYPE 2 DIABETES
    * PHASE 2A CLINICAL PROOF OF CONCEPT (POC) BIOMARKER STUDIES
OF
PXL065 AND PXL770 IN X-LINKED ADRENOLEUKODYSTROPHY (ALD) PLANNED
TO INITIATE IN EARLY 2022 WITH DATA EXPECTED BY YEAR END 2022
    * PATIENT ENROLLMENT IN PXL065 PHASE 2 (DESTINY-1) TRIAL IN
NASH
COMPLETED IN SEPTEMBER WITH RESULTS EXPECTED IN Q3 2022
    * AS OF SEPTEMBER 30, 2021, CASH AND CASH EQUIVALENTS WERE
EUR
37.2 MILLION (USD 43.2 MILLION)
    * REPORTED REVENUES OF EUR 13.3 MILLION FOR THE NINE MONTHS
ENDED
SEPTEMBER 30, 2021, AS COMPARED TO EUR 6.6 MILLION DURING THE
CORRESPONDING PERIOD IN 2020
    * PLANNING TO INITIATE TWO PHASE 2A CLINICAL PROOF OF
CONCEPT
(POC) BIOMARKER STUDIES OF PXL065 AND PXL770 IN X-LINKED
ADRENOLEUKODYSTROPHY (ALD) IN EARLY 2022

Source text for Eikon:  ID:nBw2zVVGVa 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))